Cancer name Hepatocellular Carcinoma
Cancer Type LIHC
Immunotherapy type Oncolytic viruses
Treatment Ad-ΔB/ING4
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Cell
Signature CD31-positive endothelial cells
Official Symbol Lymphatic endothelial cell
Mode of action CE_D_DOWN
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Next, to identify the possible anti angiogenic effects, these tumor tissues were also examined by IHC and ELISA to measurethe intra-tumoral levels of CD31-positive endothelial cells(CD31), vascular endothelial growth factor (VEGF), and microvascular density (MVD), as the key mediators for tumor angiogenesis and neovascularization.Compared to PBS-treated tumors,therapy with Ad-ΔB/TRAIL and Ad-ΔB/ING4 had favourably cooperated to repress the intratumoral expression of these three investigated angiogenic factors.
PMID 28925992
Title Efficacy of combining ING5 and TRAIL genes in cancer-targeting gene virotherapy strategy: first evidence in preclinical hepatocellular carcinoma